{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/fungal-skin-infection-scalp/","result":{"data":{"firstChapter":{"id":"8a51d4c9-69eb-58f9-ac0b-38f666f1f848","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 66f835e5-5d75-4e34-8618-1dfaddcf72ac --><h1>Fungal skin infection - scalp: Summary</h1><!-- end field 66f835e5-5d75-4e34-8618-1dfaddcf72ac -->","htmlStringContent":"<!-- begin item f071ee9f-496a-4ad3-b627-d12da80348ed --><!-- begin field 2624298e-f770-42a0-abf4-e1aeb6f085f4 --><ul><li>Fungal infection of the scalp is also known as 'tinea capitis' or 'scalp ringworm', and it describes infection of scalp hair follicles and the surrounding skin caused by dermatophytes.<ul><li>In UK cities, infection is usually caused by <em>Trichophyton tonsurans</em>. In Europe and rural parts of the UK, infection is usually caused by Microsporum canis.</li><li>It predominantly affects prepubertal Afro-Caribbean children.</li></ul></li><li>The clinical features of fungal scalp infection vary depending on the degree of inflammatory response, and include:<ul><li>Scaling and itch of the scalp, patches of hair loss.</li><li>Skin erythema, pustules, crusting, and lymphadenopathy.</li><li>Painful, pustular boggy masses, which may have a thick crust (kerion).</li><li>Associated fungal infection at other sites.</li></ul></li><li>Assessment of suspected fungal scalp infection should include skin and hair sampling for fungal microscopy and culture, to confirm the diagnosis and identify the underlying cause.</li><li>Management of fungal scalp infection should include:<ul><li>Advice on self-care strategies including surface crust removal; discarding or disinfecting objects that can transmit infection; inspecting other family members or household pets for signs of infection.</li><li>In adults, starting oral antifungal treatment before or after fungal microscopy and culture results are back, depending on clinical judgement.</li><li>In children, starting oral antifungal treatment if there is a confirmed diagnosis and sufficient prescribing experience in primary care, or seeking specialist advice before initiating treatment.</li><li>Co-prescribing a topical antifungal agent to reduce the risk of transmission to other people.</li><li>Reviewing the person 4–8 weeks after completing the course of oral antifungal therapy to assess the response to treatment.</li></ul></li><li>If oral antifungal treatment is initiated in primary care, either oral griseofulvin (licensed) or oral terbinafine (off-label) should be prescribed empirically, until culture results are available.<ul><li>If the person lives in an urban area, terbinafine should be started (and continued if the infecting organism is <em>Trichophyton tonsurans</em>).</li><li>If the person lives in a rural area, griseofulvin should be started (and continued if the infecting organism is Microsporum species). Oral itraconazole use (off-label indication) can be considered if griseofulvin is not tolerated or is contraindicated.</li></ul></li><li>If there are signs of treatment failure:<ul><li>Repeat skin and hair sampling for fungal microscopy and culture should be arranged, and first-line oral antifungal therapy may be continued for a further 2–4 weeks if there are signs of clinical improvement but ongoing positive mycology.</li></ul></li><li>Referral to a dermatology specialist should be arranged if:<ul><li>The person has a suspected kerion (urgent referral).</li><li>Oral antifungal treatment is being considered for a child, and there is insufficient experience and expertise to initiate this in primary care.</li><li>The diagnosis is uncertain.</li><li>Treatment in primary care is unsuccessful.</li><li>There is a suspected complication which is not responding to treatment in primary care.</li></ul></li><li>If a person is a known contact of a person with confirmed fungal scalp infection:<ul><li>Skin and hair sampling for fungal culture should be arranged to determine if the contact has confirmed infection or is an asymptomatic carrier.</li></ul></li></ul><!-- end field 2624298e-f770-42a0-abf4-e1aeb6f085f4 --><!-- end item f071ee9f-496a-4ad3-b627-d12da80348ed -->","topic":{"id":"2366ecbc-4749-5ca6-8bc3-3873089df3da","topicId":"0fd8e2d0-69ae-41e6-b283-543453f673bc","topicName":"Fungal skin infection - scalp","slug":"fungal-skin-infection-scalp","aliases":[],"chapters":[{"id":"8a51d4c9-69eb-58f9-ac0b-38f666f1f848","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"97441633-de03-58fd-9e1b-bb42c2828337","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"7bc5a70d-2277-5bff-9951-bb0c0ab337ef","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"f9145ac8-339e-59bb-b8ad-25b709acdacb","slug":"changes","fullItemName":"Changes"},{"id":"d0c182d2-7ce4-57e0-9dee-362b0b530365","slug":"update","fullItemName":"Update"}]},{"id":"6f048cdd-1cbb-5611-a5e0-8361b221db8a","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"599dbe6a-d7a3-5f91-91ed-4be709b1180c","slug":"goals","fullItemName":"Goals"},{"id":"84c3bfe1-6c40-57e4-a749-77a9946a89e3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ac49d0bf-50dc-5071-a82b-62723de01de5","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"60065f70-8af3-5f60-9dca-ff069607e2bc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fba31ad2-44ba-5fe6-bf46-7345ab044a0e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d12ccb71-eddd-5517-8749-1217ba0b4eb6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ba0c5ffb-2309-5d72-90e0-4c09ec2762ad","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"a7a6e00a-8e02-5305-be1d-1aa4389187a5","slug":"definition","fullItemName":"Definition"},{"id":"a7f24440-b63f-56f4-8c94-3bb4b1877412","slug":"prevalence","fullItemName":"Prevalence"},{"id":"015c5679-e685-58cd-b557-2ed3559a9603","slug":"complications","fullItemName":"Complications"},{"id":"8fa3f79d-ba1c-5733-8306-100d8afeabfb","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"fa2925a0-ec3e-5255-b9f9-7959141a2e82","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"b464e67b-56da-51d3-a0d4-4577dd9c24f7","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"4d8408bc-15aa-5151-a55a-b7849dcb8387","slug":"assessment","fullItemName":"Assessment"},{"id":"67ef57a0-32a1-5271-8ef9-7a7e9e1e5a24","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"05c0fb7d-20c2-5b68-9935-1d3c3f46f68d","slug":"management","fullItemName":"Management","subChapters":[{"id":"263ea5e0-37c2-539f-8fd6-e1218c2c16a1","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"2c583161-dd9d-5bf1-9fb1-a1395842cac9","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"b923eed5-33a1-596e-974f-5611050a47c7","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"eb8ea077-2ef7-5dd1-b454-43ca5a07d5a0","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin"},{"id":"599d0b59-095a-52c5-8bd1-289c5e9c48af","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"e6d4f0f1-7501-5b3f-9954-957d8152ffb7","slug":"topical-antifungals","fullItemName":"Topical antifungals"}]},{"id":"cc03af24-7789-56ce-978f-b905a9611cb5","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"ce8e8c93-7919-5160-9ad5-965fcd16658f","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"e05609c9-c42a-5eec-b055-39a296c3e2ea","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e4f27b22-bcda-54f2-83f3-4ebf35f962ba","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0ce2862f-cdca-57b0-9998-9bc40799914a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7e057656-6867-5510-95c7-019671326f4b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"687c951d-457b-52b6-93f8-e38d5eafe6ed","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f17589e6-56a0-535c-aa03-0856855943bb","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"2366ecbc-4749-5ca6-8bc3-3873089df3da","topicId":"0fd8e2d0-69ae-41e6-b283-543453f673bc","topicName":"Fungal skin infection - scalp","slug":"fungal-skin-infection-scalp","aliases":[],"topicSummary":"Fungal infection of the scalp (scalp ringworm or tinea capitis) is caused by dermatophytes and is most common among prepubescent children.","lastRevised":"Last revised in April 2018","nextPlannedReviewBy":"2023-04-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2023-03","nextPlannedReviewByDisplay":"March 2023","specialities":[{"id":"e9e3ea2b-52b8-5242-bc9d-24052ea8647a","name":"Child health","slug":"child-health"},{"id":"e174a859-759f-5b1d-898e-1a4155645e13","name":"Infections and infestations","slug":"infections-infestations"},{"id":"50071c38-ab10-5ab8-ac70-6bd19a96c24e","name":"Skin and nail","slug":"skin-nail"}],"chapters":[{"id":"8a51d4c9-69eb-58f9-ac0b-38f666f1f848","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"97441633-de03-58fd-9e1b-bb42c2828337","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"7bc5a70d-2277-5bff-9951-bb0c0ab337ef","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"f9145ac8-339e-59bb-b8ad-25b709acdacb","slug":"changes","fullItemName":"Changes"},{"id":"d0c182d2-7ce4-57e0-9dee-362b0b530365","slug":"update","fullItemName":"Update"}]},{"id":"6f048cdd-1cbb-5611-a5e0-8361b221db8a","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"599dbe6a-d7a3-5f91-91ed-4be709b1180c","slug":"goals","fullItemName":"Goals"},{"id":"84c3bfe1-6c40-57e4-a749-77a9946a89e3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ac49d0bf-50dc-5071-a82b-62723de01de5","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"60065f70-8af3-5f60-9dca-ff069607e2bc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fba31ad2-44ba-5fe6-bf46-7345ab044a0e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d12ccb71-eddd-5517-8749-1217ba0b4eb6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ba0c5ffb-2309-5d72-90e0-4c09ec2762ad","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"a7a6e00a-8e02-5305-be1d-1aa4389187a5","slug":"definition","fullItemName":"Definition"},{"id":"a7f24440-b63f-56f4-8c94-3bb4b1877412","slug":"prevalence","fullItemName":"Prevalence"},{"id":"015c5679-e685-58cd-b557-2ed3559a9603","slug":"complications","fullItemName":"Complications"},{"id":"8fa3f79d-ba1c-5733-8306-100d8afeabfb","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"fa2925a0-ec3e-5255-b9f9-7959141a2e82","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"b464e67b-56da-51d3-a0d4-4577dd9c24f7","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"4d8408bc-15aa-5151-a55a-b7849dcb8387","slug":"assessment","fullItemName":"Assessment"},{"id":"67ef57a0-32a1-5271-8ef9-7a7e9e1e5a24","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"05c0fb7d-20c2-5b68-9935-1d3c3f46f68d","slug":"management","fullItemName":"Management","subChapters":[{"id":"263ea5e0-37c2-539f-8fd6-e1218c2c16a1","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"2c583161-dd9d-5bf1-9fb1-a1395842cac9","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"b923eed5-33a1-596e-974f-5611050a47c7","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"eb8ea077-2ef7-5dd1-b454-43ca5a07d5a0","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin"},{"id":"599d0b59-095a-52c5-8bd1-289c5e9c48af","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"e6d4f0f1-7501-5b3f-9954-957d8152ffb7","slug":"topical-antifungals","fullItemName":"Topical antifungals"}]},{"id":"cc03af24-7789-56ce-978f-b905a9611cb5","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"ce8e8c93-7919-5160-9ad5-965fcd16658f","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"e05609c9-c42a-5eec-b055-39a296c3e2ea","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e4f27b22-bcda-54f2-83f3-4ebf35f962ba","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0ce2862f-cdca-57b0-9998-9bc40799914a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7e057656-6867-5510-95c7-019671326f4b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"687c951d-457b-52b6-93f8-e38d5eafe6ed","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f17589e6-56a0-535c-aa03-0856855943bb","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"2366ecbc-4749-5ca6-8bc3-3873089df3da"}},"staticQueryHashes":["3666801979"]}